← Catalyst calendarPCSA biotech catalysts & pipeline
PROCESSA PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
VT-7208 — Clinical data readout
H2 2027
Concurrent with the acquisition of Vidya, we entered into a definitive agreement for a private placement financing to raise approximately $200 million in gross proceeds, which we expect to use to support the advancement of VT-7208 through multiple clinical milestones, including data from a Phase 2 proof-of-concept study in food allergy anticipated in the second half of 2027, data from a Phase 2 proof-of-concept study in CSU anticipated in the first half of 2028, and data from a Phase 2 proof-of-concept study in RMS anticipated in the second half of 2028.
Source filingVT7208 — Clinical data readout
H2 2027
We intend to initiate this trial in the second half of 2026 and expect to report proof of concept data in the second half of 2027.
Source filingVT7208 — Clinical data readout
H1 2028
We intend to initiate this trial in the second half of 2026 and expect to report proof of concept data in the first half of 2028.
Source filingVT-7208 — Clinical data readout
H2 2028
Concurrent with the acquisition of Vidya, we entered into a definitive agreement for a private placement financing to raise approximately $200 million in gross proceeds, which we expect to use to support the advancement of VT-7208 through multiple clinical milestones, including data from a Phase 2 proof-of-concept study in food allergy anticipated in the second half of 2027, data from a Phase 2 proof-of-concept study in CSU anticipated in the first half of 2028, and data from a Phase 2 proof-of-concept study in RMS anticipated in the second half of 2028.
Source filingVT7208 — Clinical data readout
H2 2028
We intend to initiate this trial in the first half of 2027 and expect to report proof of concept data in the second half of 2028.
Source filingExplore the free biotech catalyst calendar
